Literature DB >> 2280797

Involvement of cholecystokinin receptors in the control of striatal dopamine autoreceptors.

S Tanganelli1, K Fuxe, G von Euler, L F Agnati, L Ferraro, U Ungerstedt.   

Abstract

The interaction of locally perfused cholecystokinin-8 (sulphated) with systemically administered apomorphine was studied on the release of dopamine and its metabolites using microdialysis in the neostriatum of the halothane-anaesthetized male rat. Dialysate levels of dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid were assayed by high performance liquid chromatography in combination with electrochemical detection. Perfusion with cholecystokinin-8 (100 microM but not 1 microM or 10 nM) increased the dialysate levels of dopamine without affecting those of DOPAC or HVA. At low concentrations (1 microM and 10 nM but not 1 nM), cholecystokinin-8 counteracted the inhibitory effect of apomorphine (0.05 mg/kg, s.c.) on dopamine release. This counteraction was antagonized by perfusion with the cholecystokinin-8 antagonist proglumide (3 microM). At this concentration, proglumide perfused alone was without effect on basal or apomorphine-reduced levels of dopamine. The results indicate a facilitatory effect of cholecystokinin-8 on dopamine release in rat neostriatum only at high concentrations. At lower concentrations, cholecystokinin-8 appears to modulate dopamine release by an inhibitory effect on dopamine autoreceptors possibly involving an intramembrane interaction between presynaptic cholecystokinin-8 receptors and dopamine autoreceptors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2280797     DOI: 10.1007/bf00169441

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  25 in total

1.  Effects of cholecystokinin peptides and neurotensin on dopamine release and metabolism in the rostral and caudal part of the nucleus accumbens using intracerebral dialysis in the anaesthetized rat.

Authors:  M Ruggeri; U Ungerstedt; L F Agnati; V Mutt; A Härfstrand; K Fuxe
Journal:  Neurochem Int       Date:  1987       Impact factor: 3.921

2.  Changes in pituitary-adrenal activity affect the binding properties of striatal dopamine D-2 receptors but not their modulation by neurotensin and cholecystokinin-8.

Authors:  G von Euler; K Fuxe; S Tanganelli; U B Finnman; P Eneroth
Journal:  Neurochem Int       Date:  1990       Impact factor: 3.921

3.  Effects of locally applied D-1 and D-2 receptor agonists and antagonists studied with brain dialysis.

Authors:  A Imperato; G Di Chiara
Journal:  Eur J Pharmacol       Date:  1988-11-08       Impact factor: 4.432

4.  Monoamine metabolites: their relationship and lack of relationship to monoaminergic neuronal activity.

Authors:  J W Commissiong
Journal:  Biochem Pharmacol       Date:  1985-04-15       Impact factor: 5.858

Review 5.  Modulation of neurotransmitter release by presynaptic autoreceptors.

Authors:  K Starke; M Göthert; H Kilbinger
Journal:  Physiol Rev       Date:  1989-07       Impact factor: 37.312

6.  Further studies on the specificity of proglumide as a selective cholecystokinin antagonist in the central nervous system.

Authors:  B S Bunney; L A Chiodo; A S Freeman
Journal:  Ann N Y Acad Sci       Date:  1985       Impact factor: 5.691

7.  Cholecystokinin neuron systems and their interactions with the presynaptic features of the dopamine neuron systems. A morphometric and neurochemical analysis involving studies on the action of cholecystokinin-8 and cholecystokinin-58.

Authors:  K Fuxe; L F Agnati; J J Vanderhaeghen; K Tatemoto; K Andersson; P Eneroth; A Härfstrand; G Von Euler; R Toni; M Goldstein
Journal:  Ann N Y Acad Sci       Date:  1985       Impact factor: 5.691

8.  Proglumide: selective antagonism of excitatory effects of cholecystokinin in central nervous system.

Authors:  L A Chiodo; B S Bunney
Journal:  Science       Date:  1983-03-25       Impact factor: 47.728

9.  Effects of apomorphine on the in vivo release of dopamine and its metabolites, studied by brain dialysis.

Authors:  T Zetterström; U Ungerstedt
Journal:  Eur J Pharmacol       Date:  1984-01-13       Impact factor: 4.432

10.  Characterization of dopamine autoreceptor and [3H]spiperone binding sites in vitro with classical and novel dopamine receptor agonists.

Authors:  J Lehmann; M Briley; S Z Langer
Journal:  Eur J Pharmacol       Date:  1983-03-18       Impact factor: 4.432

View more
  4 in total

Review 1.  Receptor-receptor interactions as an integrative mechanism in nerve cells.

Authors:  M Zoli; L F Agnati; P B Hedlund; X M Li; S Ferré; K Fuxe
Journal:  Mol Neurobiol       Date:  1993 Fall-Winter       Impact factor: 5.590

2.  Changes in pituitary-adrenal activity affect the apomorphine- and cholecystokinin-8-induced changes in striatal dopamine release using microdialysis.

Authors:  S Tanganelli; K Fuxe; G von Euler; P Eneroth; L F Agnati; U Ungerstedt
Journal:  J Neural Transm Gen Sect       Date:  1990

3.  Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist.

Authors:  M Poncelet; M Arnone; M Heaulme; N Gonalons; C Gueudet; V Santucci; O Thurneyssen; P Keane; D Gully; G Le Fur
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

Review 4.  Diversity and Bias through Receptor-Receptor Interactions in GPCR Heteroreceptor Complexes. Focus on Examples from Dopamine D2 Receptor Heteromerization.

Authors:  Kjell Fuxe; Alexander Tarakanov; Wilber Romero Fernandez; Luca Ferraro; Sergio Tanganelli; Malgorzata Filip; Luigi F Agnati; Pere Garriga; Zaida Diaz-Cabiale; Dasiel O Borroto-Escuela
Journal:  Front Endocrinol (Lausanne)       Date:  2014-05-13       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.